Latest News and Press Releases

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrsta ársfjórðungs 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 7. maí nk. Uppgjörsfundur með greinendum, sem sendur er út í...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Vandœuvre-lès-Nancy, le 29 avril 2025 – 18 : 00 (CET) Communiqué de presse Pour diffusion immédiate Résultats Annuels 2024 de la Société PAT Premier résultat d'exploitation positif depuis la...

Er-Kim signs distribution agreement with Polaris Pharmaceuticals to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region

MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in...

Alvotech acquires all Xbrane's operations and Cimizia biosimilar candidate, further expanding development capabilities, considers listing on Swedish market

VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Vandœuvre-lès-Nancy, le 28 février 2025 - 18 : 30 (CET) Communiqué de pressePour diffusion immédiate Hausse du Chiffre d’Affaires Combiné 2024 Chiffre d’affaires combiné non audité en progression à...